Page last updated: 2024-11-05

tranexamic acid and Carcinoma, Ovarian Epithelial

tranexamic acid has been researched along with Carcinoma, Ovarian Epithelial in 2 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Carcinoma, Ovarian Epithelial: A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.

Research Excerpts

ExcerptRelevanceReference
"High-dose tranexamic acid is more effective in reducing blood loss and blood transfusion without increasing the risk of postoperative complications."5.69Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial. ( Chai, M; He, Z; Wu, X; Xia, L; Yang, X; Zhang, J, 2023)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Yang, X1
Chai, M1
Xia, L1
He, Z1
Wu, X1
Zhang, J1
Lemoine, A1
Lambaudie, E1
Bonnet, F1
Leblanc, E1
Alfonsi, P1

Reviews

1 review available for tranexamic acid and Carcinoma, Ovarian Epithelial

ArticleYear
[Perioperative care of epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF a
    Gynecologie, obstetrique, fertilite & senologie, 2019, Volume: 47, Issue:2

    Topics: Analgesia, Patient-Controlled; Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Carcinoma, Ova

2019

Trials

1 trial available for tranexamic acid and Carcinoma, Ovarian Epithelial

ArticleYear
Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial.
    Acta obstetricia et gynecologica Scandinavica, 2023, Volume: 102, Issue:7

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical

2023